Shanghai Pharmaceuticals Holding Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceutical" or "Company") is a large pharmaceutical industry group listed in both Shanghai and Hong Kong (stock code: 02607 on the Hong Kong Stock Exchange; stock code: 601607 on the Shanghai Stock Exchange). Ranked among the Fortune Global 500 and Global 50 Pharmaceutical Companies, with a comprehensive strength ranking among the top three Chinese pharmaceutical companies. Selected as a component of the Shanghai 180 Index, Shanghai and Shenzhen 300 Index, and the Morgan Stanley China Index (MSCI). Shanghai Pharmaceutical advocates the core values of "innovation, integrity, cooperation, inclusiveness, and responsibility", committed to perseverance, improving the quality of people's healthy lives, and striving to become a respected and industry-renowned leading brand drug manufacturer and health service provider. Shanghai Pharmaceutical adheres to innovative development, continuously increases investment in research and development innovation, and accelerates innovation transformation and development. Enriching innovative drug pipelines through the "self research+introduction" model. In 2022, the company's innovative drug pipeline has made significant progress. Currently, I001 has completed the enrollment of all participants in the Phase III clinical phase and entered the second phase of safety observation and follow-up; The key clinical study on the indications for chronic abnormal immune activation of I008-A AIDS has been completed, and the CSR has been finalized and submitted to Pre NDA; I022 has obtained FDA clinical trial qualification and initiated the Phase II clinical trial of liposarcoma; The new acute stroke drug I037, which collaborates with Taiwan Shuntian Pharmaceutical, has completed clinical phase I trials and started clinical phase II trials; The application for marketing license for X842 for reflux esophagitis was accepted by the National Drug Administration on February 9, 2023. There are 62 new drug pipelines that have been accepted for clinical applications and entered the subsequent clinical research stage, including 50 innovative drugs (including 3 clinical phase II drugs in the United States) and 12 improved new drugs. In the innovative drug management line, 2 have submitted pre NDA or marketing applications, and 6 are in the critical research or clinical phase III. Strengthening innovation platform cooperation and expanding the company adheres to the concept of open cooperation and win-win, and continues to carry out high-level innovation cooperation with leading universities, medical institutions, and research institutes in the early incubation of innovative drugs, construction of clinical research platforms, and innovation and secondary development of traditional Chinese medicine. We explore innovative cooperation models, establish an innovation research and development platform that closely connects industry, academia, and research, and continuously stimulate innovation vitality. The company's industrial manufacturing covers the fields of chemical and biological drugs, modern Chinese medicine and health products, medical devices, etc., focusing on seven major treatment fields: anti-tumor, cardiovascular and cerebrovascular, psychiatric, anti infection, autoimmune, digestion and metabolism, and respiratory system. The company has established drug production bases in 12 provinces and cities in China and overseas, producing approximately 700 drug varieties and over 20 dosage forms annually. In 2022, the company has produced over 48 billion products, and multiple drugs have passed quality certifications such as WHO, FDA, and the European Union, and are sold in overseas markets. The company has 21 rare disease drug varieties, involving 34 rare disease symptoms. Under the guidance of the overall strategy of the group, the industrial manufacturing sector adheres to the basic principles of quality first, cost optimization, green development, and intelligent manufacturing. Driven by system capabilities, it aims to achieve excellent operations and intelligent manufacturing, and comprehensively transform and upgrade the entire value chain of industrial manufacturing. Shanghai Pharmaceutical is the second largest national pharmaceutical circulation enterprise and a leading import drug service platform in China. The company's distribution network covers 31 provinces, municipalities, and autonomous regions across the country, including 25 provinces, municipalities, and autonomous regions directly covered by holding subsidiaries, covering over 32000 medical institutions of various types. The retail network is distributed in 16 provinces, municipalities, and cities across the country, with a total of over 2000 retail pharmacies. The company has established strategic partnerships with major pharmaceutical manufacturers both domestically and internationally, continuously promoting service innovation, and leading industry value innovation by providing integrated supply chain services and innovative service solutions such as modern logistics, information technology services, financial services, and omnichannel integrated marketing services, gradually transforming into a "technology-based health service enterprise". The company actively promotes the upgrading of the supply chain of domestic drugs and health products, utilizing technology and information technology to leverage its platform advantages, accelerating resource collaboration, and continuously expanding new services, varieties, and markets through new mechanisms. In the field of "Internet plus" enabling innovative services, the company actively incubates the "Internet plus" medical business technology platform. Shangyao Cloud Health deeply integrates "online+offline", comprehensively develops the beneficial drug ecosystem, and provides a valuable and accessible sales and service network for the vigorous development of innovative drugs. Magnum Health is committed to deeply integrating the insurance field and the medical field, opening the ecological closed-loop of "Internet plus+medicine+medicine+insurance", providing professional supporting services for China's inclusive insurance projects, and serving the construction goal of China's multi-level medical security system. |
| Headquarter | Shanghai |
| Establish Date | 1/18/1994 |
| Listed Code | 601607.SH |
| Listed Date | 3/24/1994 |
| Chairman | Zhou Jun. |
| CEO | Shen Bo. |
| Website | www.sphchina.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
